Clopidogrel (Clopidogrel)

Trade Name : Clopidogrel

Teva Pharmaceuticals USA, Inc.

TABLET, FILM COATED

Strength 75 mg/1

CLOPIDOGREL BISULFATE Decreased Platelet Aggregation [PE],P2Y12 Platelet Inhibitor [EPC],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 2C8 Inhibitors [MoA]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Clopidogrel (Clopidogrel) which is also known as Clopidogrel and Manufactured by Teva Pharmaceuticals USA, Inc.. It is available in strength of 75 mg/1 per ml. Read more

Clopidogrel (Clopidogrel) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • The effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 Clopidogrel at recommended doses forms less of the active metabolite and so has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 gene, (termed u201cCYP2C19 poor metabolizersu201d). Tests are available to identify patients who are CYP2C19 poor metabolizers Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.
  • WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE
  • See full prescribing information for complete boxed warning.
  • Effectiveness of clopidogrel depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (, )
  • Tests are available to identify patients who are CYP2C19 poor metabolizers. ()
  • Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers. ()
  • Clopidogrel tablets are a P2Y platelet inhibitor indicated for:
  • Acute coronary syndrome
  • For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. ()
  • For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. ()
  • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. ()
  • No data
  • Acute coronary syndrome ()
  • Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily.
  • Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days.
  • Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose ()
  • Tablets: 75 mg ()
  • No data
  • Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage ()
  • Hypersensitivity to clopidogrel or any component of the product ()
  • No data
  • CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. ()
  • Bleeding: Clopidogrel increases risk of bleeding. ()
  • Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. ()
  • Thrombotic thrombocytopenic purpura (TTP) has been reported. ()
  • Cross-reactivity among thienopyridines has been reported. ()
  • The following serious adverse reactions are discussed below and elsewhere in the labeling:
  • Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. ()
  • To report SUSPECTED ADVERSE REACTIONS, contact TEVA Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
  • No data
  • Opioids: Decreased exposure to clopidogrel. Consider use of parenteral antiplatelet agent. ()
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (, , )
  • Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations. ()
  • No data
  • Platelet inhibition by clopidogrel is irreversible and will last for the life of the platelet. Overdose following clopidogrel administration may result in bleeding complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons. Symptoms of acute toxicity were vomiting, prostration, difficult breathing, and gastrointestinal hemorrhage in animals.
  • Based on biological plausibility, platelet transfusion may restore clotting ability.
  • Clopidogrel bisulfate, USP is a thienopyridine class inhibitor of P2Y ADP platelet receptors. Chemically it is methyl (+)-()-u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4)-acetate sulfate (1:1).
  • The structural formula is as follows:
  • CHClNOSu2022HSO u00a0u00a0u00a0u00a0M.W. 419.9
  • Clopidogrel bisulfate, USP is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56u00b0.
  • Clopidogrel bisulfate, USP for oral administration is provided as light-pink to pink, debossed, film-coated, unscored, capsule shaped tablets containing 97.875 mg of clopidogrel bisulfate, USP which is the molar equivalent of 75 mg of clopidogrel base.
  • Each tablet contains the following inactive ingredients: crospovidone, hydrogenated vegetable oil, hydroxypropyl cellulose, hypromellose, indigo carmine aluminum lake FD&C blue #2, iron oxide red, iron oxide yellow, lactose, lactose monohydrate, microcrystalline cellulose, polyethylene glycol, sodium lauryl sulfate, and titanium dioxide.
  • No data
  • There was no evidence of tumorigenicity when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats at dosages up to 77 mg/kg per day, which afforded plasma exposures >25 times that in humans at the recommended daily dose of 75 mg.
  • Clopidogrel was not genotoxic in four tests (Ames test, DNA-repair test in rat hepatocytes, gene mutation assay in Chinese hamster fibroblasts, and metaphase chromosome analysis of human lymphocytes) and in one test (micronucleus test by oral route in mice).
  • Clopidogrel was found to have no effect on fertility of male and female ratsu00a0treated prior to pairing and throughout gestation at oral doses up to 400 mg/kg per day (52 times the recommended human dose on a mg/mbasis).
  • No data
  • Clopidogrel Tablets USP are available as follows:
  • 75 mg u2013 light-pink to pink, film-coated, unscored, capsule shaped tablets debossed with u201cTVu201d on one side and u201c7314u201d on the other side, in bottles of 30, 90, and 500.
  • NDC 0093-7314-56 Bottle of 30
  • NDC 0093-7314-98 Bottle of 90
  • NDC 0093-7314-05 Bottle of 500
  • Store at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F) [See USP Controlled Room Temperature].
  • Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
  • KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
  • Advise patients to read FDA approved patient labeling (Medication Guide).
  • Discontinuationn n- [see Warnings and Precautions ()].
  • Bleeding
  • Advise patients that they:
  • Thrombotic Thrombocytopenic Purpura
  • Instruct patients to get prompt medical attention if they experience symptoms of TTP that cannot otherwise be explained n
  • Invasive Procedures
  • Advise patients to inform physicians and dentists that they are taking clopidogrel before any surgery or dental procedure n
  • Proton Pump Inhibitors
  • Advise patients not to take omeprazole or esomeprazole while taking clopidogrel. Dexlansoprazole, lansoprazole and pantoprazole had less pronounced effects on the antiplatelet activity of clopidogrel than did omeprazole or esomeprazole n
  • Manufactured In Israel By:n n Jerusalem, 9777402, Israeln Manufactured For:n North Wales, PA 19454
  • Rev. L 8/2019
  • Clopidogrel Tablets
  • (kloe-PID-oh-grel)n
  • Read this Medication Guide before you start taking clopidogrel tablets and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.
  • What is the most important information I should know about clopidogrel tablets?
  • 1.n
  • 2. Clopidogrel tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. While you take clopidogrel tablets:
  • Call your doctor right away if you have any of these signs or symptoms of bleeding:
  • Do not stop taking clopidogrel tablets without talking to the doctor who prescribes them for you. People who stop taking clopidogrel tablets too soon have a higher risk of having a heart attack or dying. If you must stop clopidogrel tablets because of bleeding, your risk of a heart attack may be higher.
  • What are clopidogrel tablets?
  • Clopidogrel tablets are a prescription medicine used to treat people who have any of the following:
  • Clopidogrel tablets are used alone or with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clot that can lead to death.
  • Platelets are blood cells that help your blood clot normally. Clopidogrel tablets help to prevent platelets from sticking together and forming a clot that can block an artery.
  • It is not known if clopidogrel tablets are safe and effective in children.
  • Who should not take clopidogrel tablets?
  • Do not take clopidogrel tablets if you:
  • What should I tell my doctor before taking clopidogrel tablets?
  • Before you take clopidogrel tablets, tell your doctor if you:
  • Tell all of your doctors and your dentist that you are taking clopidogrel tablets. They should talk to the doctor who prescribed clopidogrel tablets for you before you have any surgery or invasive procedure.
  • Tell your doctor about all the medicines you take
  • Clopidogrel tablets may affect the way other medicines work, and other medicines may affect how clopidogrel tablets work. See u201cu201d
  • Clopidogrel tablets may increase blood levels of other medicines such as repaglinide (Prandin).
  • Taking clopidogrel tablets with certain other medicines may increase your risk of bleeding. n
  • Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.
  • How should I take clopidogrel tablets?
  • What are the possible side effects of clopidogrel tablets?
  • Clopidogrel tablets can cause serious side effects including:
  • Tell your doctor if you have any side effect that bothers you or that does not go away. Tell your doctor if you develop an allergic reaction including skin reactions while taking clopidogrel tablets.
  • These are not all the possible side effects of clopidogrel tablets. For more information, ask your doctor or pharmacist.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • How should I store clopidogrel tablets?
  • Keep clopidogrel tablets and all medicines out of the reach of children.
  • General information about clopidogrel tablets
  • Medicines are sometimes used for purposes other than those listed in a Medication Guide. Do not take clopidogrel tablets for a condition for which they were not prescribed. Do not give clopidogrel tablets to other people, even if they have the same symptoms that you have. They may harm them.
  • This Medication Guide summarizes the most important information about clopidogrel tablets. If you would like more information, talk to your doctor. Ask your doctor or pharmacist for information about clopidogrel tablets that was written for healthcare professionals.
  • For more information, call 1-888-838-2872.
  • What are the ingredients in clopidogrel tablets?
  • Active ingredient:
  • Inactive ingredients:
  • This Medication Guide has been approved by the U.S. Food and Drug Administration.
  • All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA, Inc.
  • Manufactured In Israel By:n n Jerusalem, 9777402, Israeln Manufactured For:n n North Wales, PA 19454
  • Rev. F 8/2019
  • No data

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.